Literature DB >> 12672070

Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.

Claudia Monari1, Cinzia Retini, Arturo Casadevall, Dale Netski, Francesco Bistoni, Thomas R Kozel, Anna Vecchiarelli.   

Abstract

Disseminated infections by the opportunistic yeast Cryptococcus neoformans are characterized by accumulation in tissues of glucuronoxylomannan (GXM), the major component of the capsular polysaccharide. We investigated binding, uptake, and disposal of GXM by peripheral blood neutrophils and monocytes, and the effect of GXM uptake on phagocytic cell function. GXM was efficiently bound and internalized by both types of phagocytic cells, with maximal loading at 50 microg/ml, a GXM concentration found in serum and cerebrospinal fluid of some cryptococcosis patients. However, substantial differences were noted in the kinetics for uptake by macrophages and neutrophils. Whereas neutrophils rapidly ingested limited amounts of GXM and then expelled or degraded it after 1 h of incubation, macrophages demonstrated continuous intracellular accumulation for up to 1 week of incubation. Accumulation of GXM by neutrophils was accompanied by reduced anticryptococcal activity, suggesting one more mechanism for virulence enhancement by the major capsular component of C. neoformans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672070     DOI: 10.1002/eji.200323388

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  18 in total

1.  Capsular Material of Cryptococcus neoformans: Virulence and Much More.

Authors:  A Vecchiarelli; C Monari
Journal:  Mycopathologia       Date:  2012-02-08       Impact factor: 2.574

2.  Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.

Authors:  Zong Liang Chang; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo.

Authors:  Lauren E Yauch; Michael K Mansour; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 4.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

5.  A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharide.

Authors:  M Piccioni; C Monari; S Bevilacqua; S Perito; F Bistoni; T R Kozel; A Vecchiarelli
Journal:  Clin Exp Immunol       Date:  2011-05-23       Impact factor: 4.330

6.  Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis.

Authors:  Luciana Tissi; Manuela Puliti; Francesco Bistoni; Paolo Mosci; Thomas R Kozel; Anna Vecchiarelli
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

7.  Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo.

Authors:  Lauren E Yauch; Michael K Mansour; Shmuel Shoham; James B Rottman; Stuart M Levitz
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Isolation and purification of antigenic components of Cryptococcus.

Authors:  Karen L Wozniak; Stuart M Levitz
Journal:  Methods Mol Biol       Date:  2009

Review 9.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

10.  Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo.

Authors:  Allan Jefferson Guimarães; Susana Frases; Radamés J B Cordero; Leonardo Nimrichter; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Cell Microbiol       Date:  2010-01-11       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.